Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds.

On May 19, Wolfe Research initiated Tyra Biosciences, Inc. (NASDAQ:TYRA) with a Peer Perform rating and no price target. The analyst stated dabogratinib could “achieve the CR bar for LR IR NMIBC” while remaining “on the fence” pending safety de-risking.

On May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) reported Q1 results, advancing its “dabogratinib 3×3” strategy, dosing the first LG-UTUC patient in SURF303, and targeting initial results in 2027. Cash stood at $383.5 million, funding operations into 2H 2028.

The company posted a net loss of $39.3 million from $28.1 million a year earlier and raised R&D expenses to $33.5 million.

Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

Photo by National Cancer Institute on Unsplash

CEO Todd Harris said the firm “continues to advance with steady progress,” flagging multiple data readouts in 2026.

Chief Medical Officer Doug Warner noted dabogratinib may “represent a meaningful shift” in treatment, pointing to the Phase 2 studies across three indications.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a precision oncology firm that develops purpose-built treatments to overcome tumor resistance and improve cancer patients’ outcomes.

While we acknowledge the risk and potential of TYRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TYRA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1